Hutchison China Meditech Limited Chi-Med Presents at JPM Healthcare Conference

TIDMHCM

Hutchison China Meditech Limited

07 January 2019

Press Release

Chi-Med to Present at the 37(th) Annual JP Morgan Healthcare Conference

London: Monday, January 7, 2019: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37(th) Annual JP Morgan Healthcare Conference on Wednesday, January 9, 2019 at 9:30am PST in San Francisco, CA.

The presentation will be webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under "Events, Circulars & Forms." Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter, for 90 days.

About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 400 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President                               [phone] 
  Annie Cheng, Vice President                                   [phone] 
  David Dible, Citigate Dewe Rogerson                           [phone] (Mobile) 
                                                                [e-mail] 
  Xuan Yang, Solebury Trout                                     [phone] (Mobile) 
                                                                 [e-mail] 
 
Media Enquiries 
  UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson        [phone] (Mobile) 
                                                                 [e-mail] 
  Americas - Brad Miles, Solebury Trout                         [phone] (Mobile) 
                                                                 [e-mail] 
  Hong Kong & Asia ex-China      - Joseph Chi Lo, Brunswick     [phone] (Mobile) 
                                                                 [e-mail] 
                                 - Zhou Yi, Brunswick           [phone] (Mobile) 
                                                                 [e-mail] 
  Mainland China - Sam Shen, Edelman                            [phone] (Mobile) 
                                                                 [e-mail] 
 
Nominated Advisor 
  Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited      [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAQDLBBKFFZBBF

(END) Dow Jones Newswires

January 07, 2019 02:00 ET (07:00 GMT)